GlassScriptPhysician profile
Cheryl J King
NPI 1588693154
$4,965.64
in general payments reported to CMS, 2019-2025
34 companies · $375 in 2025
The $375 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $572 · 2021: $1,401 · 2022: $1,230 · 2023: $681 · 2024: $706 · 2025: $375.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,762.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,762.04 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $1,367.73 | 2020-2025 | Mounjaro, Jardiance, Emgality |
| Novo Nordisk INC | $543.18 | 2020-2025 | Ozempic, Rybelsus, Wegovy |
| Abbvie INC. | $309.32 | 2021-2024 | |
| Amgen INC. | $298.97 | 2020-2025 | Repatha, Otezla, Repatha |
| Astrazeneca Pharmaceuticals LP | $281.95 | 2020-2025 | Farxiga, Breztri, Airsupra |
| Avanir Pharmaceuticals, INC. | $229.12 | 2020-2021 | |
| Sanofi-Aventis U.S. LLC | $228.76 | 2020-2025 | |
| Glaxosmithkline, LLC. | $200.33 | 2021-2023 | Trelegy Ellipta |
| Astellas Pharma US INC | $197.95 | 2021-2022 | |
| Corcept Therapeutics | $189.90 | 2021-2023 | Korlym |
| Takeda Pharmaceuticals U.S.A., INC. | $162.52 | 2021-2022 | |
| Abbott Laboratories | $104.88 | 2022-2025 | Freestyle Libre 3 |
| Amarin Pharma, INC. | $103.36 | 2020-2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $74.67 | 2023-2025 | |
| Nestle Healthcare Nutrition INC. | $73.68 | 2020-2023 |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Esperion Therapeutics, INC. | $67.40 | 2020-2021 | |
| Merck Sharp & Dohme LLC | $66.77 | 2020-2021 | |
| Lundbeck LLC | $51.71 | 2024 | Rexulti |
| Exact Sciences Corporation | $50.54 | 2024-2025 | Cologuard Collection Kit |
| Aimmune Therapeutics, INC. | $48.74 | 2024 | |
| Atland Pharmaceuticals, LLC | $42.55 | 2024 | Tolmetin Sodium, Orphenadrine Citrate, Aspirin and Caffeine |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $40.36 | 2020-2025 | Xifaxan |
| Sumitomo Pharma America, INC. | $34.86 | 2024-2025 | Gemtesa |
| Idorsia Pharmaceuticals US INC | $30.05 | 2022 | |
| Clarus Therapeutics INC. | $20.92 | 2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $19.33 | 2020 | |
| Allergan, INC. | $19.00 | 2020 | |
| Pfizer INC. | $18.54 | 2024 | |
| Antares Pharma, INC. | $17.13 | 2022 | |
| Currax Pharmaceuticals LLC | $15.32 | 2025 | Contrave |
| Biohaven Pharmaceutical Holding Company LTD. | $15.24 | 2022 | |
| Kowa Pharmaceuticals America, INC. | $14.49 | 2020 | |
| Novartis Pharmaceuticals Corporation | $13.82 | 2022 | |
| Acerus Pharmaceuticals Corporation | $12.55 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Cheryl King listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.